Pattern Pharma's lead product, PAR-1, is the culmination of more than two decades of work by Company Principals on activators of the innate immune system which target the immune failure underlying cancers and infectious diseases. PAR-1 is administered systemically to activate monocytes/macrophages, dendritic cells (DCs) and NK cells via TLR4, and is the next generation of an earlier product which has been approved and used on millions of people. In cancer applications, these activated immune cells become tumoricidal and, since they sit at the top of the immune response stack, trigger subsequent adaptive immune responses and also enable other immune-oncology modalities such as checkpoint inhibitors. PAR-1 is also efficacious as an activator of antiviral and antibacterial immune responses. The above uses are supported by extensive animal and human data as regards both efficacy and safety. The Company utilizes a proprietary, readily-scalable process to manufacture PAR-1 and has patent applications on the product.